Syngenta IPO Pitched at $66 Billion-Plus for Hong Kong Debut

A $66 billion opening bid

Syngenta is moving closer to its long-delayed return to public markets, and its bankers have now named a price. Advisers to the Swiss-Chinese agrochemicals group are aiming for a valuation of at least $66 billion in a planned Hong Kong listing. Two people familiar with the matter told Reuters the listing will most likely happen early next year.1 UBS and China International Capital Corp (CICC), two of the sponsor banks, are pitching the Basel-based seeds and crop-protection company at 15 to 20 times its expected 2026 EBITDA.1 Applied to Syngenta's 2025 EBITDA of $4.4 billion, that range puts the company at $66 billion to $88 billion, which would make it one of the biggest IPOs anywhere next year.1

China CITIC Bank and Bank of America are also sponsors of the deal.1 Syngenta and UBS declined to comment, and the other banks did not respond to Reuters' requests.1 Every outlet covering the story so far is repeating the same Reuters scoop, by John Revill and Oliver Hirt.7 Because of that, the numbers match from one report to the next, but none of them has been confirmed publicly by the company.

The deal mechanics: stake, proceeds and timing

According to the reporting, Syngenta plans to sell 10% to 20% of the company. It would use the money to pay down debt and to invest in crop-protection products and seeds.3 The company has already filed for the listing, and the sale could raise between $5 billion and $10 billion.3 That range is wider than earlier reports suggested. A September report described a confidential Hong Kong filing aimed at raising at least $5 billion.6 Another summary of the company's IPO history puts the planned deal at about $5 billion, citing September 2026 reports. One reading is that the $10 billion upper end reflects new confidence from the bankers. Another is that it simply follows from the stake range, since 20% of a much higher valuation produces a much bigger sale. The figures support either view.

The timing is still open. Three people said a listing before the end of 2026 remains possible, but most expect a debut in early 2027. One of them said there is confidence that a January window can work.1 Bankers have been meeting investors in Shanghai, Hong Kong and Beijing, and plan further marketing in Frankfurt and London.10 Starting in mainland China and Hong Kong before Europe suggests the order book will rely heavily on Chinese and Asian investors. The European meetings look aimed at reminding investors that this was a Swiss-listed company until 2017.

Reading the multiple

The headline number depends on two inputs, and it is worth separating them. The banks' multiple is based on expected 2026 EBITDA, but the published $66 billion to $88 billion range uses 2025's $4.4 billion figure.1 If 2026 EBITDA comes in higher, the same 15 to 20 times multiple produces a higher valuation. That makes the $66 billion look more like a conservative floor than a ceiling.

The opposite risk is just as real. Finimize pointed out that with EBITDA at about $4.4 billion, each one-point change in the multiple adds or removes roughly $4.4 billion of market value, even if the business performs exactly as forecast.8 If demand is weaker during bookbuilding and the banks have to accept a multiple closer to 15 times, the price range and the proceeds could shrink without any bad news from the business.8

The reports also differ on one basic figure. Reuters says 2025 EBITDA rose 17% from the year before.1 A summary citing Syngenta's own full-year results says it grew 13%.12 A separate review of the company's financials also gives 13%, and adds that group sales fell 1% to $28.4 billion in 2025. That review shows the China business shrinking 10% while crop protection grew 4%. So on these figures, the growth story rests on margin improvement more than on rising sales. Investors will look closely at that difference once a prospectus is published.

The biotech pitch

The bankers' argument is about how the company is described. People familiar with the matter said the valuation reflects Syngenta's effort to present itself as a biotechnology company rather than a chemicals producer.3 One of them pointed to a strong crop-protection lineup and a pipeline of new seed varieties that resist disease and pests as reasons for a premium.10 Syngenta sells seeds, herbicides, insecticides and fungicides, as well as biological and digital farming products. It employs more than 50,000 people in more than 90 countries.3

This is the key bet behind the valuation. Syngenta competes with BASF, Bayer and Corteva.5 In our view, the bankers are asking investors to treat it as a science-driven growth company rather than a commodity input supplier. Whether 15 to 20 times EBITDA holds up will depend on whether investors accept that the seed pipeline and biologicals business make Syngenta different from its peers. The sources also say some Asian investors are taking a fresh interest in traditional industrial companies as enthusiasm for AI-related stocks cools.5 That suggests the bankers are presenting Syngenta both as a biotech story and as a lower-risk option for investors moving out of technology.

Hong Kong's hot market, with a cooling edge

The market backdrop is mostly favourable. HKEX data show 118 new listings raised HK$388.0 billion ($49.5 billion) in the first nine months of 2026, up 106% from a year earlier.1 A listing of this size would fit Hong Kong's push to attract large fundraisings by companies with Chinese ties. Finimize described the deal as a test of whether global investors will pay premium prices for a China-controlled multinational when geopolitics and disclosure expectations affect demand.8

The broad Reuters version of the story includes a caution that some shorter versions leave out. Sentiment weakened in October after a selloff in AI-related stocks raised doubts about valuations and returns on AI spending. Changzhou Microintelligence and Jiangsu Slender West Lake Culture and Tourism both postponed their offerings, citing market conditions.13 On the day the valuation news spread, Dongshan Precision shares fell 2.1% in their Hong Kong debut.3 None of this rules out a January deal. It does mean the market Syngenta enters may be tougher than the year-to-date totals suggest.

A listing years in the making

The IPO would revive Sinochem's attempt to take Syngenta public after it withdrew a planned Shanghai listing in 2024.13 The history matters. ChemChina bought Syngenta for $43 billion in 2017, still China's largest foreign takeover. ChemChina was then merged into Sinochem in 2021, creating the world's biggest industrial chemicals company.1 Before the takeover, Syngenta traded on the New York Stock Exchange and the SIX Swiss Exchange, and it was delisted from both when the deal closed.

The route back to public markets has been slow. One timeline shows a 2021 application for a Shanghai main-board listing targeting about $10 billion, withdrawn in March 2024 after three years. It then shows a Hong Kong plan reported in February 2026, and a delay into 2027 reported in July as Middle East tensions disrupted fertiliser and crop markets. Leadership has changed as well. Jeff Rowe, who strongly backed the IPO, stepped down as CEO in August and was replaced by chief operating officer Hengde Qin. Qin is a Chinese national seen as able to manage the various approval processes.5

Those approvals are the least visible risk. Seed production is treated as a sensitive industry in China, which may mean extra regulatory sign-offs before the listing can go ahead. Sinochem is also expected to keep control after the float, so outside investors will hold a minority stake in a company run by the state.

The verdict

All the reporting points the same way. Syngenta's advisers are setting a high bar, the window is early 2027, and Hong Kong is the venue. In our view, $66 billion is a credible opening position rather than an overreach, for two reasons. The valuation range is calculated on last year's earnings even though the multiple is meant to apply to this year's. And the company has a long record of published financials, which most IPO candidates do not.1

What will decide the final price is investor appetite, not the arithmetic. The deal needs international investors to accept a biotech-style multiple for a state-controlled agrochemicals company in a sector Beijing treats as sensitive. It also needs Hong Kong's market to hold up after October's setbacks. If both happen, Syngenta could become one of next year's defining listings. If either falls short, a few points off the multiple would bring the headline valuation down quickly.